XVIVO Perfusion extends the acceptance period for the public offer on Vivoline Medical

The Offer is not made, and this press release may not, directly nor indirectly,
be distributed in or to, Australia, Hong Kong, Japan, Canada, New Zeeland, South
Africa or the U.S or in any other country where making of the Offer,
distribution of this press release or acceptance of the Offer would be contrary
to applicable laws or rules or would require further offering documentation or
registration or any other measures in addition to what is required by Swedish
law.

XVIVO Perfusion AB (“XVIVO Perfusion”) announced on 18 April 2016 a recommended
public offer to the holders of shares (“Shares”) and warrants of series
2015/2016 (“Warrants”) in Vivoline Medical AB (“Vivoline”) to transfer all of
their Shares and Warrants to XVIVO Perfusion (the “Offer”). At the expiry of the
ordinary acceptance period on 7 June 2016, 10,774,457 Shares (corresponding to
94.5 percent of the total number of Shares) and 4,132,943 Warrants
(corresponding to 96.8 percent of the total number of Warrants) had been
submitted in the Offer. Against this background, XVIVO Perfusion declared the
Offer unconditional and extended the acceptance period until and including
20 June 2016.

During the extended acceptance period, 288,135 Shares (corresponding to 2.5
percent of the total number of Shares) and 88,327 Warrants (corresponding to 2.1
percent of the total number of Warrants) have been submitted in the Offer.
Accordingly, a total of 11,062,592 Shares (corresponding to 97.0 percent of the
total number of Shares) and 4,221,270 Warrants (corresponding to 98.9 percent of
the total number of Warrants) have been submitted in the Offer. XVIVO Perfusion
has not acquired any Shares or Warrants outside of the Offer and does not hold
any Shares or Warrants or other financial instruments that entails a financial
exposure which corresponds to a holding of Shares or Warrants in Vivoline.
Payment of consideration to the holders of Shares and Warrants that have
accepted the Offer during the extended acceptance period will begin around 23
June 2016. The board of XVIVO Perfusion has consequently resolved upon a new
issue of not more than 52,082 shares in XVIVO Perfusion with payment in kind
consisting of Shares and Warrants.

In order to grant the remaining holders of Shares and Warrants more time to
accept the Offer, the acceptance period is being extended until and including 14
July 2016. Payment of the consideration to the holders of Shares and Warrants
that accept the Offer during the extended acceptance period may be made
continuously. However, the final payments of the consideration are estimated to
be made around 20 July 2016.

XVIVO Perfusion reserves the right to further extend the acceptance period.

XVIVO Perfusion has initiated a compulsory redemption process of the remaining
Shares and Warrants. In addition, Vivoline has on 17 June 2016 announced that
the Shares and Warrants will be delisted from Nasdaq First North and that the
last trading day in the Shares and Warrants will be 8 July 2018.

The information provided herein is such that XVIVO Perfusion is obligated to
disclose pursuant to the Takeover Rules. The information was submitted for
publication at 7.30 a.m. CET, 21 June 2016.

For further information, please contact:

Magnus Nilsson, CEO
+46 (0)31-788 21 50
magnus.nilsson@xvivoperfusion.com

Gothenburg 21 June 2016
XVIVO Perfusion AB (publ)

IMPORTANT INFORMATION

The Offer is not being made to persons whose participation in the Offer requires
that any additional offer document or prospectus is prepared or registration
effected or that any other measures are taken in addition to those required
under Swedish laws and rules.

This press release and any other documentation relating to the Offer are not
being distributed and must not be mailed or otherwise distributed or sent in or
into any country in which distribution or offering would require any such
additional measures to be taken or would be in conflict with any law or
regulation in such country – XVIVO Perfusion will not allow or accept any such
measure. Any purported acceptance of the Offer resulting directly or indirectly
from a violation of these restrictions may be disregarded.

The Offer is not being made and will not be made, directly or indirectly, by use
of mail or any other communication means or facility, either by
intergovernmental nature or for foreign trade or through national stock
exchanges’ facilities, in or into Australia, Hong Kong, Japan, Canada, New
Zealand, South Africa or the U.S. This includes, without limitation, facsimile
transmission, electronic mail, telex, telephone and the internet or other forms
of electronic distribution. The Offer cannot be accepted and Shares and Warrants
cannot be transferred in the Offer, by any such measures, means, instrumentality
or facility of, or from within Australia, Hong Kong, Japan, Canada, New Zealand,
South Africa or the U.S. or by persons that are located in, or resident in
Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S.
Accordingly, this press release and any documentation related to the Offer are
not being and should not be mailed or otherwise distributed, forwarded or sent
in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the
U.S. or to a person that is located in, or resident in Australia, Hong Kong,
Japan, Canada, New Zealand, South Africa or the U.S.

Every attempt to transfer Shares or Warrants in the Offer which, directly or
indirectly, is a result of a violation of these restrictions is invalid and
every attempt to transfer Shares or Warrants by a person who is located in
Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S. or by
representatives, agents or other intermediary who acts on non-discretionary
basis for a principal who delivers instructions from or within Australia, Hong
Kong, Japan, Canada, New Zealand, South Africa or the U.S. is invalid and will
not be accepted. Every person who holds Shares or Warrants and who participates
in the Offer will certify that the person is not from, or is not located in or
deliver instructions to participate in the Offer from, Australia, Hong Kong,
Japan, Canada, New Zealand, South Africa or the U.S., and that they are not
acting on a non-discretionary basis on behalf of a principal who is from, is
located in or gives an order to participate in the Offer from Australia, Hong
Kong, Japan, Canada, New Zealand, South Africa or the U.S. XVIVO Perfusion will
not deliver any consideration in accordance with the Offer in or into Australia,
Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S.

This press release is not being, and must not be, sent to holders of Shares or
Warrants with registered addresses in Australia, Hong Kong, Japan, Canada, New
Zealand, South Africa or the U.S. Banks, brokers, dealers and other nominees
holding Shares or Warrants for persons in Australia, Hong Kong, Japan, Canada,
New Zealand, South Africa or the U.S. may not forward this press release or any
other document received in connection with the Offer to such persons.

The term “U.S.” shall in this section have the meaning the United States of
America, its territories and dependencies (including Puerto Rico, American
Virgin Islands, Guam, American Samoa, Wake Islands and Commonwealth of the
Northern Mariana Islands), every state within the United States of America and
the Columbia District.

Forward-looking statements

Statements in this press release relating to future status or circumstances,
including statements regarding future performance, growth and other trend
projections and the other benefits of the Offer, are forward-looking statements.
These statements may generally, but not always, be identified by the use of
words such as “anticipates”, “intends”, “expects”, “believes”, or similar
expressions. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will
occur in the future. There can be no assurance that actual results will not
differ materially from those expressed or implied by these forward-looking
statements due to many factors, many of which are outside the control of XVIVO
Perfusion. All such forward-looking statements are only valid as of the day when
the statements were made and XVIVO Perfusion does not have any obligations (and
does not undertake any obligation) to update or audit the statements, as a
consequence of new information, future occurrences or other circumstances,
except as required according to law and other regulation.
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com